
Biotech
Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
NORCROSS, Ga., Jan. 05, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today that in late December 2022, it ended enrollment of NAVIGATE, its seamless, more...

Biotech
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in more...

Biotech
CTI BioPharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
CTI BioPharma to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire SEATTLE , Jan. 5, 2023 /PRNewswire/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at more...

Mining
American Lithium Receives Approval to List on NASDAQ
VANCOUVER, British Columbia, Jan. 05, 2023 (GLOBE NEWSWIRE) — American Lithium Corp. (“American Lithium” or the “Company”) (TSX-V:LI | OTCQB:LIACF | Frankfurt:5LA1) is pleased to announce it has received approval to list its common shares more...

Tech
Lantronix to Present at 25th Annual Needham Growth Conference on Jan. 11, 2023
IRVINE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Industrial Internet of Things (IoT) and the Intelligent IT market, today announced that its more...

Biotech
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh PR Newswire Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of more...

Biotech
EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines
– Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 more...

Biotech
Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) — Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, more...

Biotech
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TIG, SESN, CBIO
NEW YORK, NY / ACCESSWIRE / January 5, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary more...

Mining
AVINO VEIN EXTENDED A FURTHER 315 METRES
AVINO VEIN EXTENDED A FURTHER 315 METRES PR Newswire Drills 248 AgEq g/t over 16.66 metres including 371 AgEq g/t over 8.57 metre s VANCOUVER, BC , Jan. 5, 2023 /PRNewswire/ – Avino Silver & more...